Qianjiang Yongan Pharmaceutical Co Ltd Cash Flow Reinvestment Rate
Qianjiang Yongan Pharmaceutical Co Ltd cash flow reinvestment rate. Qianjiang Yongan Pharmaceutical Co Ltd (002365) has a Cash Flow Reinvestment Rate of 0.20x as of September 2025, reinvesting CN¥11.85 Million (capex CN¥11.85 Million ) from operating cash flow of CN¥58.18 Million. Explore Qianjiang Yongan Pharmaceutical Co Ltd (002365) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Qianjiang Yongan Pharmaceutical Co Ltd (2006–2024)
Cash flow reinvestment rate of Qianjiang Yongan Pharmaceutical Co Ltd from 2006 to 2024. Historical reinvestment intensity for Qianjiang Yongan Pharmaceutical Co Ltd across 19 annual periods. Explore Qianjiang Yongan Pharmaceutical Co Ltd capex to cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
Qianjiang Yongan Pharmaceutical Co Ltd Cash Flow Reinvestment Rate by Year (2006–2024)
Qianjiang Yongan Pharmaceutical Co Ltd cash flow reinvestment rate by year from 2006 to 2024. Year-by-year capital reinvestment analysis for Qianjiang Yongan Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see 002365 cash flow conversion.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 1.77x | CN¥186.81 Million | CN¥105.71 Million | CN¥118.04 Million | ▲ +128.2% |
| 2023 | 0.77x | CN¥189.15 Million | CN¥244.26 Million | CN¥120.74 Million | ▲ +16.4% |
| 2022 | 0.67x | CN¥257.76 Million | CN¥387.28 Million | CN¥149.07 Million | ▼ -58.9% |
| 2021 | 1.62x | CN¥165.02 Million | CN¥101.81 Million | CN¥63.05 Million | ▼ -4.6% |
| 2020 | 1.70x | CN¥351.06 Million | CN¥206.66 Million | CN¥104.41 Million | ▲ +98.9% |
| 2019 | 0.85x | CN¥204.59 Million | CN¥239.55 Million | CN¥134.39 Million | ▼ -38.0% |
| 2018 | 1.38x | CN¥432.37 Million | CN¥314.02 Million | CN¥269.50 Million | ▼ -11.4% |
| 2017 | 1.55x | CN¥306.65 Million | CN¥197.32 Million | CN¥289.47 Million | ▲ +29.0% |
| 2016 | 1.20x | CN¥101.83 Million | CN¥84.53 Million | CN¥40.13 Million | ▲ +149.3% |
| 2015 | 0.48x | CN¥34.12 Million | CN¥70.61 Million | CN¥34.12 Million | ▼ -81.6% |
| 2014 | 2.63x | CN¥50.69 Million | CN¥19.26 Million | CN¥50.69 Million | ▲ +67.6% |
| 2013 | 1.57x | CN¥99.93 Million | CN¥63.65 Million | CN¥99.93 Million | ▼ -7.6% |
| 2012 | 1.70x | CN¥120.18 Million | CN¥70.75 Million | CN¥120.18 Million | ▼ -37.5% |
| 2011 | 2.72x | CN¥248.03 Million | CN¥91.23 Million | CN¥248.03 Million | ▲ +14.6% |
| 2010 | 2.37x | CN¥104.52 Million | CN¥44.06 Million | CN¥104.52 Million | ▲ +87.9% |
| 2009 | 1.26x | CN¥45.98 Million | CN¥36.43 Million | CN¥45.98 Million | ▲ +177.0% |
| 2008 | 0.46x | CN¥72.19 Million | CN¥158.47 Million | CN¥72.19 Million | ▼ -54.2% |
| 2007 | 0.99x | CN¥60.77 Million | CN¥61.08 Million | CN¥60.77 Million | ▲ +75.1% |
| 2006 | 0.57x | CN¥17.68 Million | CN¥31.11 Million | CN¥17.68 Million | — |